Cutaneous squamous cell carcinoma progression during imiquimod treatment

Dika, Emi; Fanti, Pier ­Alessandro; Lambertini, Martina; Scarfì, Federica; Ravaioli, Giulia Maria; Veronesi, Giulia; Baraldi, Carlotta; Guglielmo, Alba; Patrizi, Annalisa

doi:10.1016/j.jaad.2018.02.079

Cited by 9 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 As Imiquimod enhances Th1 cytokine production and diminishes Th2 mediators, it may influence the immunosurveillance and tumor editing processes 7 . 8 The induction of F I G U R E 1 Clinical images of, A, recurrent in-transit metastases of malignant melanoma (MM) of the right leg in an over 89-year-old woman: pink papules and nodules of the right leg. B, Treatment of intransit MM metastases: 5% imiquimod cream 5 days a week after diathermocoagulation ablation.…”

Section: In Transit Melanoma and Imiquimod: A Case Of Disease Progressionmentioning

confidence: 99%

In transit melanoma and imiquimod: A case of disease progression

Dika

Ravaioli

Melotti

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Section: In Transit Melanoma and Imiquimod: A Case Of Disease Progressionmentioning

confidence: 99%

In transit melanoma and imiquimod: A case of disease progression

Dika

Ravaioli

Melotti

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

“…In patients with large, advanced cSCC in whom adapted intense immunocryosurgery schemes were applied as a palliative modality, these initially responded but subsequently relapsed and had to be treated with another approach. Notably, relapses, or the emergence of metastasis, have been reported with imiquimod monotherapy [52], although isolated reports describe effective treatment of cSCC, even with imiquimod monotherapy [53][54][55][56][57]. Immunocryosurgery is more effective in the case of relatively stable cSCC, i.e., tumors that have not grown more than 20% the last 12 months, in elderly patients and under close clinical follow up it can be recommended in order to treat timely recognized probable relapses or delayed responses (Figure 4).…”

Section: Cutaneous Squamous Cell Carcinomamentioning

confidence: 99%

A Review of Immunocryosurgery and a Practical Guide to Its Applications

Gaitanis

Bassukas

2021

Diseases

View full text Add to dashboard Cite

Immunocryosurgery is a minimally invasive combinational therapeutic procedure that has been designed, developed, and evaluated in the Dermatology Department of the University of Ioannina from 2004. In a fixed time protocol, this approach combines immune stimulatory therapy with imiquimod and cryosurgery, i.e., cryosurgery is applied during continuous imiquimod treatment. Laboratory findings in tissue and blood level credit the efficacy to the synergy of imiquimod and cryosurgery. The synergy has been established through clinical trials and the excellent feasibility and efficacy demonstrated in clinical practice. Immunocryosurgery has extensive proof of excellent efficacy, comparable to surgery, in the treatment of basal cell carcinoma. It has also been evaluated in cases of Bowen’s disease, keratoacanthoma, Merkel cell carcinoma, lentigo maligna, and cutaneous squamous cell carcinoma with or without the addition of adjuvants. The aims of this review are to detail the immunocryosurgery protocol with the addition of daily practice clinical tips, compile data on the mechanism of action of immunocryosurgery, and delineate indications and possible future applications. Most of the available data originate from the treatment of BCC, of all histological types and localizations, and the principles reported mainly reflect on evidence related to the treatment of this common skin cancer.

show abstract

“…Imiquimod is an effective form of immunotherapy for the treatment of AK and FC [ 16 ]. It is an immune response modifier that activates immune cells via toll-like receptor 7, initiating a cascade leading to the induction of cytokines, such as interferon alfa, interferon gamma, and interleukin 12, which promote a T helper 1 (TH1) immune response [ 36 ].…”

Section: Therapeutic Managementmentioning

confidence: 99%

Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization

Piquero-Casals¹,

Morgado‐Carrasco

Gilaberte

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Field cancerization (FC) is a chronic disease involving multiple clinical and subclinical actinic keratoses (AK) on large photo-exposed surfaces with multifocal areas of dysplasia and precancerous changes. Patients and treatment must be properly monitored and managed to avoid aggravation and progression of the disease. Management of actinic keratoses includes lesion-directed treatments, such as cryotherapy and field-directed therapies. Field-directed therapies may have the potential to address subclinical damage, reduce AK recurrence rates and potentially reduce the risk of squamous cell carcinoma development. Multiple studies have demonstrated the efficacy of field-directed treatments, including 5-fluorouracil, photodynamic therapy, imiquimod, chemical exfoliation with trichloroacetic acid and diclofenac gel, for multiple AK and FC. The choice of therapy should be based on multiple factors, such as efficacy, tolerability, patient risk profile, costs and cosmetic results. Management of AK includes not only treatment but also prevention. Medical devices, such as sunscreens containing liposome-encapsulated DNA repair enzymes, can repair DNA damage associated with chronic UV radiation and reduce the number of new AK lesions. Here we provide therapeutic pearls and expert opinions on the treatment of AK and FC (as monotherapy or in combination) with the overall aim to achieve better, faster, and well-tolerated clinical responses.

show abstract

Cutaneous squamous cell carcinoma progression during imiquimod treatment

Cited by 9 publications

References 6 publications

In transit melanoma and imiquimod: A case of disease progression

In transit melanoma and imiquimod: A case of disease progression

A Review of Immunocryosurgery and a Practical Guide to Its Applications

Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization

Contact Info

Product

Resources

About